Prostate Cancer Coverage from Every Angle

Michael J. Morris, MD: Can Lutetium-177–PSMA-617 Plus Standard of Care Improve Outcomes in Advanced Prostate Cancer?

Posted: Tuesday, June 15, 2021

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses implications of the VISION trial findings, which suggest a targeted radioligand therapy appears to benefit men with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. Should it prove beneficial beyond the clinical trial, the next question would be whether it would require specialized facilities.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.